Version June 2024
| Conventional central chondrosarcoma | Conventional peripheral chondrosarcoma | Periosteal chondrosarcoma | Dedifferentiated chondrosarcoma | Mesenchymal chondrosarcoma | Clear cell chondrosarcoma | |
| Percent of all chondrosarcomas | ~75 percent | ~10 percent | <1 percent | ~10 percent | <2 percent | <2 percent |
| Precursor lesion | Enchondroma (up to 40 percent?) | Osteochondromas (100 percent) | None | Conventional chondrosarcoma | None | None |
| Occurrence within syndrome | Enchondromatosis (Ollier disease) | Multiple osteochondromas | None | Rarely in multiple osteochondromas or enchondromatosis | None | None |
| Age | >50 years | Younger than central chondrosarcoma | Peak at fourth decade | Median age 59 years | Any age (peak at second to third decade) | Any age (peak in third to fifth decade) |
| Preferential location | Pelvis, proximal femur, proximal humerus, distal femur, ribs | Pelvis, shoulder girdle bones | Distal femur and humerus | Femur and pelvis | 65 to 86 percent skeleton (jawbones, ribs, ilium, vertebrae) 14 to 43 percent extraosseous (meninges) | Epiphysis of humeral or femoral head |
| Histological grading | Atypical cartilaginous tumour/chondrosarcoma grade 1 (ACT/CS1), grade 2 or 3 | Prognosis usually good despite worrisome histology | High grade | High grade | Low grade | |
| Survival | ACT/CS1: 83 percent Grade 2: 64 percent Grade 3: 29 percent All at 10 years | 24 percent at five years | 28 percent at 10 years | 89 percent at 10 years | ||
| Sensitivity to conventional chemotherapy | None | None | None | Uncertain | Possibly, if high percentage round cells | None |
| Sensitivity to radiotherapy | Low | Low | Low | Low | Possibly high | Low |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
